New Asthma Treatment: Hype vs. Reality—Expensive Injections, Limited Access
Research from King’s College London reveals benralizumab, an injectable drug already used for severe cases, as the first new asthma attack treatment in 50 years. Targeting eosinophils, a type of white blood cell contributing to lung inflammation, the therapy significantly reduced treatment failure rates compared to steroids (45% vs. 74%) in a 158-person trial. This new approach offers improved symptoms, quality of life, and reduced hospitalizations, potentially impacting the two million asthma attacks annually in the UK. While further large-scale trials are needed, the findings suggest a potential “game-changer” in asthma and COPD treatment.
John Q. Hosedrinker